A preliminary pharmacodynamic overview of objective measures of intoxication in regular and fast-acting cannabis edibles.

Sturgess K.; DiCecco S.; Habib M.; Smith E.; Karoly H.; Villanueva C.; Hennesy M.; Conner B. · Psychopharmacology · 2026

**Background & Methods** This preliminary pharmacodynamic review examined objective physiological markers of cannabis intoxication across different edible formulations. Twenty participants completed a within-subjects design comparing cardiovascular and thermoregulatory responses following consumption of a fast-acting cannabis edible, a standard cannabis edible, and a placebo edible. **Key Findings** - Blood pressure changes were similar between fast-acting and standard cannabis edibles, with both products producing comparable effects throughout the intoxication time course compared to placebo. - Significant heart rate elevations were observed in both the standard edible and fast-acting edible conditions, though fast-acting and standard formulations demonstrated only small but statistically significant differences from one another; notably, heart rate remained elevated at onset across all conditions (including placebo) and decreased over the session duration. - No significant differences in body temperature were detected across time or experimental conditions, suggesting temperature is not a reliable objective marker of cannabis edible intoxication. **Dosage & Administration** Not reported. **Safety & Adverse Effects** Not reported. The study focused exclusively on objective cardiovascular and thermoregulatory parameters without reporting subjective adverse effects or safety concerns. **Evidence Quality** This preliminary review has several important limitations. The study employed a small sample size (n=20) and lacked specification of cannabinoid content (THC/CBD dosages) in the edible products tested. The counterintuitive finding that heart rate remained elevated across all conditions, including placebo, raises questions about confounding variables such as anticipatory anxiety or environmental factors. The within-subjects design is appropriate for detecting pharmacodynamic changes but limits generalizability, particularly regarding individual variability in cannabis responsiveness. Notably, the abstract does not specify timing of measurements or report statistical parameters (p-values, effect sizes), limiting interpretation of clinical significance. The finding of small differences between fast-acting and standard edibles requires larger studies with standardized dosing to clarify whether delivery system differences produce clinically meaningful physiological distinctions. This represents preliminary evidence (Level 3-4) requiring confirmatory research with larger, more diverse populations and comprehensive reporting of cannabinoid content, dosing schedules, and both objective and subjective intoxication measures.

More recent cannabis research